BPC-157 and TB-500 are structurally unrelated peptides: BPC-157 is a 15-amino-acid sequence patterned on a protein in human gastric juice, while TB-500 is a 7-amino-acid acetylated fragment of thymosin beta-4. No study has compared them head to head and neither has a human trial, so this comparison covers chemistry and evidence only, with no recommendation.
The short version
These two are frequently discussed as interchangeable members of a category. Structurally they have almost nothing in common. One is a 15-residue peptide patterned on a sequence from human gastric juice; the other is a 7-residue fragment of a 43-residue actin-binding protein. They are different sizes, from different biological systems, with different proposed mechanisms, and their literatures have different weaknesses.
Side by side
| BPC-157 | TB-500 | |
|---|---|---|
| Length | 15 amino acids | 7 amino acids |
| Sequence | GEPPPGKPADDAGLV | Ac-LKKTETQ |
| Origin | Based on a partial sequence from human gastric juice protein | Fragment 17-23 of thymosin beta-4, N-terminally acetylated |
| Relationship to a parent | A designed peptide patterned on a natural sequence | A literal fragment of a larger natural protein |
| Molar mass | ~1,419.5 g/mol (free acid) | ~889 g/mol (acetylated 7-mer) |
| Proposed mechanism | Angiogenesis, associated with VEGF signalling | Actin binding and sequestration, affecting cell migration |
| Literature volume | Large, but concentrated in one research lineage | Smaller for the fragment; large for the parent protein |
| Key literature caveat | Much of it from a single research group | Most cited studies used the 43-residue protein, not the fragment |
| Human trials of the compound sold | None | None |
| Regulatory status | Not approved anywhere; FDA has flagged it in compounding | Not approved anywhere; prohibited in sport |
The structural difference that matters most
Each compound has a different relationship to its “parent,” and this is the crux.
BPC-157 is a synthetic peptide whose 15-residue sequence is patterned on a portion of a protein found in human gastric juice. It is studied as itself. When a paper says “BPC-157,” the material tested is the same kind of molecule sold under that name.
TB-500 is different, and this is where most comparisons go wrong. Analytical work published in Drug Testing and Analysis identified commercial TB-500 as the N-terminally acetylated fragment covering residues 17-23 of thymosin beta-4 – seven amino acids, Ac-LKKTETQ (Esposito et al., 2012, PMID 22962027). But the great majority of famous “thymosin beta-4” studies used the full 43-residue protein. So a citation count that looks impressive for “TB-500” is substantially a citation count for a different, six-times-larger molecule.
That asymmetry means the two compounds are not comparable on evidence volume in the way a naive count suggests. BPC-157’s literature is about BPC-157. A large share of TB-500’s apparent literature is about its parent protein.
What the research on each has actually examined
Fuller detail lives in the individual overviews: BPC-157 and the TB-500 + BPC-157 blend article, which covers TB-500 in depth.
BPC-157 – Chang et al., 2011, Journal of Applied Physiology
Model: rat Achilles tendon plus isolated tendon fibroblasts (cell culture)
Researchers examined how tendon repair-cells behaved when exposed to BPC-157 and recorded increased cell outgrowth and migration in the dish, alongside changes measured at the tendon in the rats.
Limitations: rats and isolated cells, not humans; small animal groups.
BPC-157 – Sikiric et al., 2020, Gut and Liver (review)
Scope: review of preclinical gastrointestinal and organ-protection research
Collects a large number of animal experiments reporting associations between BPC-157 and protective measures in various injury models.
Limitations: a review of animal work, much of it from a single research lineage; adds no human evidence; publication and funding bias are relevant considerations.
TB-500 region – Philp et al., 2003, Wound Repair and Regeneration
Model: full-thickness skin wounds in db/db diabetic mice and aged mice
One of the few studies to test the short fragment alongside the full protein. Researchers measured wound closure rate and reported faster closure in animals given thymosin beta-4, with the seven-residue LKKTETQ fragment producing a comparable measurement in the aged animals.
Limitations: mice; a local wound model; small groups; single research group.
TB-500 parent protein – Sosne et al., 2010, FASEB Journal (review) and Sosne et al., 2022, IJMS
Scope: review of which regions of thymosin beta-4 carry measured activity; plus a Phase 3 randomized trial of a topical ophthalmic formulation of the FULL-LENGTH protein
The review identifies short internal sequences, including the actin-binding region, as active sites in several assays – the rationale for selling a fragment at all. The 2022 trial is genuine human evidence, but for the full 43-residue protein applied topically as an investigational drug candidate.
Limitations: the human trial studied a different molecule by a different route and did not lead to an approved drug; it is not evidence about a 7-residue fragment in a research vial.
No study has compared them directly, and no study has examined them in combination either – a point worth making because they are widely sold pre-mixed. Comparing a rat tendon measurement against a mouse wound-closure measurement establishes nothing about which molecule is “better.”
Different proposed mechanisms
The mechanisms are genuinely distinct, which is the most defensible thing to say about the two together.
BPC-157 is most often discussed in terms of angiogenesis – the formation of new blood vessels – with animal and cell studies linking it to VEGF signalling, a pathway the body uses to build vasculature.
TB-500’s region relates to actin, the protein cells use to build their internal scaffolding and to move. Thymosin beta-4’s best-established role is holding actin units in reserve so a cell can rapidly rebuild that scaffolding, and cell migration depends on that machinery.
Both are mechanisms observed in animal and cell models. Neither is established in humans, and having two different proposed mechanisms is not evidence that they complement each other – which is the usual, unsupported argument for combining them.
Why this article does not tell you which to choose
Because no published evidence supports such a statement. Both are unapproved compounds with no human trial data on the material actually sold. A comparison resolving into a recommendation would be manufacturing a conclusion the literature does not contain.
What is legitimately comparable – sequence, size, origin, proposed mechanism, evidence quality, and verification requirements – is covered above. On evidence quality both are weak, in different ways: BPC-157’s volume is concentrated in one research lineage, and TB-500’s apparent volume substantially belongs to a larger molecule.
PeptSelect does not publish preparation or usage guidance for either compound, or for any peptide.
How to tell them apart, and what each certificate must show
The masses are far apart – roughly 1,419.5 versus roughly 889 – so mass spectrometry distinguishes them decisively, and also identifies a blend containing both.
Each has its own certificate trap:
- BPC-157: the salt form. An acetate or TFA salt has a different mass and registry number from the free acid, so the declared form must match the measurement.
- TB-500: acetylation. The acetylated 7-mer and the free peptide differ by about 42 daltons. Since suppliers differ on which they ship, the certificate should state it and confirm it by mass. This is also why this page publishes no CAS number for TB-500.
Beyond identity, both need a real HPLC chromatogram rather than an asserted percentage (see reading a chromatogram), a net peptide content figure, a matching batch identifier, and a named independent laboratory.
Every PeptSelect batch is matched to a published third-party certificate in the COA Vault, and the full testing process is documented in How we test.
What is the structural difference between BPC-157 and TB-500?
Do they have different molecular weights?
Has any study compared BPC-157 and TB-500 directly?
Is TB-500 the same as thymosin beta-4?
Are they ever sold together, and is that combination studied?
Which one has better evidence?
Every batch, published
Look up any batch identifier and read the third-party certificate it resolves to.
